樂觀
$387.16
情境價格
$340.920
-0.477 (-0.14%)收盤時
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
Cencora Inc is a good buy right now due to its current price of $340.92 being below the analyst price targets, with Baird and Citi both setting targets at $370. The RSI is at 87.341, indicating strong momentum, and the company has shown a solid revenue growth trend with Q2 revenue at $78.4 billion, up 3.8% year-over-year. However, a key risk is the high debt-to-equity ratio of 361.93%, which could impact financial stability.
RBC Capital
$330
2026-08-19
RBC Capital
2026-08-19
目標價
$330
Leerink
—
2026-08-12
Leerink
2026-08-12
目標價
—
Morgan Stanley
$346
2026-08-07
Morgan Stanley
2026-08-07
目標價
$346
Baird
$370
2026-08-06
Baird
2026-08-06
目標價
$370
Evercore ISI
$350
2026-08-06
Evercore ISI
2026-08-06
目標價
$350
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Cencora to Release Q4 Fiscal 2026 Results on November 4, 2026

Cencora Appoints New Independent Director

Jim Cramer Highlights Six Stocks to Buy Now

Comparing AbbVie and Johnson & Johnson for Investment

Investment Opportunities Amid Trumpflation
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).
Cencora Inc is a good buy right now due to its current price of $340.92 being below the analyst price targets, with Baird and Citi both setting targets at $370. The RSI is at 87.341, indicating strong momentum, and the company has shown a solid revenue growth trend with Q2 revenue at $78.4 billion, up 3.8% year-over-year. However, a key risk is the high debt-to-equity ratio of 361.93%, which could impact financial stability.
15 analysts cover COR: 7 rate it Buy, 8 Hold and 0 Sell. The average price target is 415.38.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。